Looking Ahead: Combinations, New Targets, and the Path to Long-Term Survival

In this final segment, our panel looks ahead at where the field is going and what the next wave of advances could mean for patients who do not yet have good options. You will hear what is on the horizon for HLA-A*02:01-negative patients, including HLA-agnostic liver-directed approaches and PRAME-targeted cell therapies in clinical development, and what combination strategies are most compelling for HLA-positive patients who could benefit from building on tebentafusp's established survival advantage. The panel closes with the three things each of them believes will have the greatest impact on outcomes in the next twelve months: universal HLA testing, earlier referral to specialized centers, and smarter sequencing as new therapies approach approval. The overall message is one of genuine optimism, uveal melanoma is no longer a disease without hope, and the trajectory of progress over the past several years suggests the next decade could be transformative.